Rubicon Research Limited manufactures pharmaceuticals in India's Healthcare sector with market cap ₹26,779.91 Crore and quarterly revenues in ₹300–530 Crore range. Company shows solid profitability: operating margins average 22.82%, ROE 19.14%, supported by conservative D/E ratio of 0.2.
Face value
₹1
Market cap
₹26,975 Cr
P/E
93.6×
P/B
20.9×
Dividend yield
0.1%
ROE
19.1%
ROCE
24.3%
Debt / equity
0.2
OPM
22.8%
EPS (TTM)
₹17.5
Book value
₹78.1
52-week high
—
52-week low
Key insights
Company research notes and source-linked reviews
Key risks
PE ratio of 92.91 embeds elevated growth expectations; assess whether current valuation leaves margin for disappointment if earnings do not expand as priced in
Quarterly revenue volatility (₹301.71 Cr Dec 2025 to ₹534.34 Cr Jun 2026) raises questions about demand consistency or execution reliability
Operating margins compressed from peaks of 29.18% (Jun 2026) to 20.63% (Dec 2025), exposing vulnerability to cost inflation or product-mix headwinds
Stock trading near 52-week highs (₹1,619.1 vs ₹1,655.1 range) limits upside cushion and increases downside risk if sentiment shifts
Generated analysis · source review pending
Growth drivers
Operating margins averaging 22.82%, peaks 29.18%, mean earnings compound at multiple of revenue growth if volume scales without margin compression
Debt-to-equity 0.2 leaves capacity to fund growth capex or M&A without financial distress, if capital deployment targets ROE of 19.14% or better
Dividend initiated Aug 2026 signals cash generation; retained earnings accelerate growth if reinvested in high-return opportunities
Generated analysis · source review pending
234 historical price candles were omitted because the exchange source has not been verified.
₹1,630.9+1.4%1Y
Quick read
rule-based
Pros
+Strong return on equity of 19.1% (3-yr avg)
+High return on capital employed of 24.3%
+Healthy operating margin of 22.8%
Cons
−Expensive at 93.6× trailing earnings
−Trading at 20.9× book value
−Low dividend payout of 8.6% of profit
Research score
Structured signal from quality, growth, valuation and momentum.
33/100
Business quality
65
Valuation
0
Revenue & net profit
₹ crore, by fiscal year
RevenuePAT
Margins
% of revenue, by fiscal year
OPMPAT margin
Peers
Comparable companies from the narrowest available industry classification.
Loading peers…
Financials
Reported profit and loss, balance sheet, cash flow and growth history.
Loading financials…
Ratios
Annual operating, return, leverage and working-capital ratios.
Loading ratios…
Shareholding
Quarterly ownership, named holders, insider transactions and disclosed deals.
Loading shareholding…
F&O
Current futures and options contracts with compact option-chain pages.
Loading f&o…
Fund holders
Mutual-fund schemes that disclosed a holding in the company.
Loading fund holders…
Documents
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Loading documents…
Events
Upcoming dates and the company’s corporate-action history.
Loading events…
Announcements
Latest exchange announcements, filings and downloadable documents.
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
1
Final dividend7 Aug 2026 · ex-date₹1.5
1
Board meeting to consider results14 Aug 2026
Not in the F&O segment
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Reporting (BRSR) PDF
3 Aug 2026, 9:48 pmAGM/EGM
Notice Of 27Th Annual General Meeting Along With Integrated Annual Report Of The Company For The Financial Year 2025-26 And Letter For Weblink To Access Notice And The Integrated Annual Report
Newspaper Advertisement Titled 'Information Regarding 27Th Annual General Meeting To Be Held Through Video Conferencing/ Other Audio-Visual Means, Final Dividend And Record Date Information
Filing Of Scheme Of Merger Of Kia Health Tech Private Limited (Wholly Owned Subsidiary) With Rubicon Research Limited - For Disclosure Purposes Only, In Terms Of The Exemption Under Paragraph 4 Of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 Dated June 20, 2023
Filing Of Scheme Of Merger Of Kia Health Tech Private Limited (Wholly Owned Subsidiary) With Rubicon Research Limited - For Disclosure Purposes Only, In Terms Of The Exemption Under Paragraph 4 Of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 Dated June 20, 2023
Notice Of 27Th Annual General Meeting Along With Integrated Annual Report Of The Company For The Financial Year 2025-26 And Letter For Weblink To Access Notice And The Integrated Annual Report
Newspaper Advertisement Titled 'Information Regarding 27Th Annual General Meeting To Be Held Through Video Conferencing/ Other Audio-Visual Means, Final Dividend And Record Date Information
Filing Of Scheme Of Merger Of Kia Health Tech Private Limited (Wholly Owned Subsidiary) With Rubicon Research Limited - For Disclosure Purposes Only, In Terms Of The Exemption Under Paragraph 4 Of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 Dated June 20, 2023
Filing Of Scheme Of Merger Of Kia Health Tech Private Limited (Wholly Owned Subsidiary) With Rubicon Research Limited - For Disclosure Purposes Only, In Terms Of The Exemption Under Paragraph 4 Of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 Dated June 20, 2023